Idiopathic pulmonary fibrosis (IPF) is an orphan disease affecting approximately 50,000 people in the United States. Characterized by the thickening and stiffening of tissues in the lungs, it…
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disorder associated with progressive inflammation and/or fibrosis of the lung tissue. The leading cause of the disorder is unknown. IPF…
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disorder characterized by an irreversible loss of lung function. Roche’s pirfenidone (Esbriet) was the first disease-modifying therapy (DMT)…
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disorder associated with progressive inflammation and/or fibrosis of the lung tissue. The leading cause of the disorder is unknown. Individuals…
Clarivate Epidemiology’s coverage of idiopathic pulmonary fibrosis (IPF) comprises epidemiological estimates of key patient populations in the emerging pharmaceutical markets (China, India,…
Clarivate Epidemiology’s coverage of idiopathic pulmonary fibrosis (IPF) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…
Clarivate Epidemiology’s coverage of idiopathic pulmonary fibrosis (IPF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of IPF…
Clarivate’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts of key idiopathic pulmonary fibrosis (IPF) patient populations covering 171…
Clarivate Epidemiology’s coverage of idiopathic pulmonary fibrosis (IPF) comprises epidemiological estimates of key patient populations in the Asia-Pacific region (Australia, Hong Kong, Indonesia…
Clarivate Epidemiology’s coverage of idiopathic pulmonary fibrosis (IPF) comprises epidemiological estimates of key patient populations in the Middle East and Africa (Egypt, Nigeria, Saudi Arabia…
Clarivate Epidemiology’s coverage of idiopathic pulmonary fibrosis (IPF) comprises epidemiological estimates of key patient populations in Europe (Austria, Belgium, Czech Republic, Denmark,…
Clarivate Epidemiology’s coverage of idiopathic pulmonary fibrosis (IPF) comprises epidemiological estimates of key patient populations in the American markets (Argentina, Canada, Chile, Colombia…